Please try another search
For the fiscal year ended 31 December 2017, OTCPharm PAO revenues increased 6% to RUR28.33B. Net income increased 17% to RUR7.22B. Revenues reflect Non-prescription pharmaceuticals segment increase of 4% to RUR27.54B, Prescription pharmaceuticals segment increase from RUR261.8M to RUR796.1M. Net income benefited from Foreign Exchange Loss decrease of 58% to RUR295.8M (expense).
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Revenue | 15509.52 | 12824.1 | 15412.46 | 11348.15 |
Gross Profit | 10435.71 | 8664.22 | 10168.99 | 7325.42 |
Operating Income | 5226.48 | 4252.73 | 5151.09 | 3300.99 |
Net Income | 3829.05 | 3395.59 | 3737.81 | 2461.03 |
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Assets | 52340.23 | 49170.95 | 47352.97 | 34438.21 |
Total Liabilities | 10442.9 | 11102.67 | 12680.28 | 3503.33 |
Total Equity | 41897.34 | 38068.29 | 34672.69 | 30934.88 |
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 2299.92 | 1835.8 | -1202.49 | 1607.62 |
Cash From Investing Activities | -1081.35 | -1033.14 | -4109.26 | -2559.02 |
Cash From Financing Activities | -2278.11 | -923.27 | 6810 | |
Net Change in Cash | -1075.18 | -184.2 | 1342.86 | -951.4 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review